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Introduction
Since its very first description, understanding the acute 
respiratory distress syndrome (ARDS) has been a major 
research and clinical challenge due to heterogeneity in 
causes, manifestations, physiologic derangements and 
response to treatment. Recently, growing evidences on 
the mechanisms underlying ARDS pathophysiology and 
randomized trials yielding negative results generated a 
worldwide collaborative effort to define more homogenous 
subgroups of ARDS subjects and titrate personalized 
interventions. A recently published trial (the LIVE study) 
tried to maximize this effort and compared for the first 
time personalized vs. conventional protective ventilation 
strategies (1). In the present article, we describe how 
ventilation in ARDS could be personalized based on sound 
pathophysiological subgroups and comment the results 
from the LIVE study. 
Personalized classification of ARDS 
The ideal definition of ARDS should reach a compromise 
between facilitating the recognition of this syndrome 
at the bedside and differentiating subgroups of patients 
with different biology, respiratory physiology, response 
to treatment and outcome. According to the Berlin 
definition (2), stratification of ARDS is based on the degree 
of oxygenation impairment assessed by the ratio of PaO2 
to FiO2 (P/F). The Berlin definition doesn’t recommend 
standardized ventilator settings, although positive end-
expiratory pressure (PEEP) and FiO2 affect the P/F. 
Moreover, it disregards other indexes of severity known to 
describe ARDS pathophysiology and predict response to 
treatment, such as dead space, lung elastance, recruitability 
and inhomogeneity (3). Although clinical studies showed 
that, on average, all these indexes progressively increase 
from mild to moderate to severe subjects according to 
the Berlin definition, large variability exists within each 
subgroup. Therefore, the stratification proposed by 
the current definition may work for increasing patient 
homogeneity in clinical studies on personalized treatments 
(i.e., use of more invasive and risky maneuvers in more 
severe subjects), but it is largely inadequate to define the 
patient-specific pathophysiology and to tailor treatment on 
individual requirements. 
In the perspective of protective mechanical ventilation, 
personalized treatment means to adjust ventilator settings 
to minimize the risk of ventilator-induced lung injury 
(VILI) in the individual patient, rather than applying 
average population-based treatments. While clinical 
trials demonstrated the benefits of limiting tidal volume 
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and plateau pressure (4), increasing understanding of the 
heterogeneous pathophysiology of ARDS opened the way 
for individualized ventilator settings based on respiratory 
mechanics, as a sound alternative to arbitrary universal 
targets (5). The description of the “baby lung” concept 
supported the idea that tidal volume (VT) needs to be scaled 
to the functional lung size (to decrease lung “strain”), 
while appreciation of the variability in lung and chest wall 
respective contribution to respiratory system elastance 
shifted the focus from airway pressure to transpulmonary 
pressure (to limit lung “stress”) (6,7). Lung recruitability 
and inhomogeneity were also shown to influence the 
physiological and clinical effect of ventilator settings. 
Since strain, stress, recruitability and inhomogeneity are 
not routinely assessed at the bedside, attempts were done 
to identify clinical sub-phenotypes with more uniform 
pathophysiology. 
The distinction between pulmonary and extra-pulmonary 
ARDS was proposed based on the direct or indirect etiology 
of lung injury. Extra-pulmonary ARDS was initially thought 
to be characterized by higher chest wall elastance and higher 
recruitability, but this was not confirmed by subsequent 
studies (8). Indeed, recent data indicate that recruitability 
is related to the severity rather than to the origin of ARDS 
but is highly inter-individually variable (3).
To further analyze the value of impaired oxygenation 
in dissecting ARDS sub-phenotypes, a P/F threshold of 
150 mmHg measured at standardized PEEP level of 
5 cmH2O was suggested to identify two populations 
with more homogenous anatomical and physiological 
characteristics (9): the mild-moderate and the moderate-
severe subjects.
Lung morphology assessed by radiological images is 
another proposed criterion for clinical phenotyping of 
ARDS (10). Compared to focal, patients with diffuse ARDS 
have lower lung compliance and higher recruitability, are 
more likely to respond to high PEEP and recruitment 
maneuvers, and are burdened by higher mortality (11).
Finally, a secondary retrospective analysis of previous 
trials led to the identification of two consistent ARDS sub-
phenotypes based on a cluster of clinical and biological 
variables: the hypo- and the hyper-inflamed. This 
confirmed that the ARDS definition encompasses diseases 
with different natural histories, clinical and biological 
characteristics and outcome (5,12). The two biological sub-
phenotypes consistently showed different or even opposite 
responses to several treatments, with the hyper-inflated 
usually responding to more aggressive strategies (i.e., higher 
PEEP) (13). 
These studies suggest that the possibility to identify 
biological sub-phenotypes at the bedside will provide 
the basis for refined personalized definition of ARDS, 
which is the prerequisite for correct implementation of 
individualized treatments (Table 1).
Table 1 Summary of personalized ARDS classification and ventilator settings
Criteria for ARDS 
classification
Sub-phenotype Tidal volume PEEP
Recruitability Higher 5–6 mL/kg PBW and DP <14 cmH2O Higher by assessing recruitment and over-distension 
by bedside method (EIT, EELV measure, mechanics)
Lower 6-8 mL/kg PBW and DP <14 cmH2O Lower PEEP/FiO2 table
Oxygenation P/F ≤150 5–6 mL/kg PBW and DP <14 cmH2O Higher by increasing Pplat to 28–30 cmH2O or 
elastance-derived PL to 20–22 cmH2O
P/F >150 6–8 mL/kg PBW and DP <14 cmH2O Lower PEEP/FiO2 table
Lung morphology Non-focal 5–6 mL/kg PBW and DP <14 cmH2O Higher by assessing recruitment and over-distension 
by bedside method (EIT, EELV measure, mechanics)
Focal 6–8 mL/kg PBW and DP <14 cmH2O Lower PEEP/FiO2 table
Inflammation Hyper-inflammatory 6 mL/kg PBW and DP <14 cmH2O Higher PEEP/FiO2 table
Hypo-inflammatory 6 mL/kg PBW and DP <14 cmH2O Lower PEEP/FiO2 table
ARDS, acute respiratory distress syndrome; PEEP, positive end expiratory pressure; PBW, predicted body weight; DP, driving pressure; 
EIT, electrical impedance tomography; EELV, end-expiratory lung volume; P/F, PaO2/FiO2 ratio; Pplat, inspiratory plateau pressure; PL, 
transpulmonary pressure.
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Personalized tidal volume
Due to edema, alveolar flooding and increased lung weight, 
ARDS is characterized by reduced size of the aerated lung 
available for tidal ventilation: the mechanical distortion 
provided by VT in this “baby lung” is the most important 
determinant of VILI. Accordingly, lowering VT is among 
the most convincing interventions capable of mitigating 
the risk of VILI and improve clinical outcome. VT size is 
conventionally scaled on predicted body weight. However, 
predicted body weight reflects total lung size and does not 
consider the extent of aeration loss and the actual lung size, 
that have high inter-subject variability. Therefore, some 
patients (i.e., those with smaller functional lung size) are at 
risk of hyperinflation even if VT is limited to 6 mL/kg of 
predicted body weight. Since respiratory system compliance 
is correlated with the aerated lung size (14), the driving 
pressure, which is the VT divided by the respiratory system 
compliance, better reflects the effects of VT setting and 
represents the ventilatory variable most strongly associated 
to clinical outcome in ARDS (15). Current evidence supports 
the use of VT lower than 6 mL/kg, especially if this is 
associated to a driving pressure greater than 14 cmH2O (16). 
The occurrence  of  VILI  depends  on regional 
overdistension in the aerated lung: this cannot be precisely 
estimated by airway pressure because of the interference 
of chest wall elastance, which is highly inter-individually 
variable. Conversely, the proportion of alveolar pressure at 
end-inspiration that is dissipated across the lung accurately 
reflects the transpulmonary pressure in the non-dependent, 
ventilated areas. This “transpulmonary plateau pressure” 
is easily calculated by multiplying plateau pressure and 
the ratio of lung to respiratory system elastance, measured 
by esophageal manometry (17): limiting VT to maintain 
transpulmonary plateau pressure below 22–24 cmH2O 
appears wise to prevent regional overdistension.
These considerations prompt the use of VT not exceeding 
6 mL/kg in ARDS patients; further limiting VT to on the 
basis of driving pressure, transpulmonary plateau pressure 
and/or electrical impedance tomography-derived signs of 
overdistension (18) appears sound but further validations 
are needed to identify safe thresholds. Hypercapnia can 
develop because of ultra-low VT strategies. Extracorporeal 
CO2 removal (ECCO2R) to facilitate VT-reduction below 
6 mL/kg is feasible (19): further research is warranted to 
identify the patients that most benefit from this approach 
and to establish whether this strategy may improve clinical 
outcome. 
Personalized PEEP
It is widely accepted that PEEP setting should aim to 
balance recruitment of collapsed lung, yielding increased 
aerated tissue for tidal ventilation, and the unavoidable 
damage caused by over-distention of already open alveoli. 
Five different randomized studies comparing higher 
versus lower PEEP, in which higher PEEP values were 
set according to plateau pressure (20), oxygenation 
impairment (21,22), to generate positive transpulmonary 
pressure (23) and to minimize driving pressure (24) failed 
to detect a benefit of high PEEP strategies. Such results 
do not support the use of high PEEP in ARDS patients: 
however, the response to PEEP in terms of recruitment 
of previously collapse alveolar units (lung recruitability) 
significantly varies among subjects, and cannot be estimated 
by changes in the driving or transpulmonary pressure nor 
by improvement in oxygenation (3). High PEEP in patients 
with low recruitability worsens lung injury and affects 
hemodynamics, while low PEEP in potentially recruiting 
patients cannot fully exert its beneficial effects on lung 
protection (25). These considerations prompted a search 
for bedside strategies to set PEEP on the basis of patient’s 
recruitability. The amount of recruitable lung is best 
investigated using computed tomography scan (3), but this 
technique may not be feasible in everyday clinical practice 
due to economical and practical issues. Recently, strategies 
available at the bedside based on lung volume measurement 
by gas dilution, electrical impedance tomography and 
simplified assessment of recruitment have been proposed 
(25,26). These appear promising to aid physiology-based 
PEEP titration based on patient’s individual response, 
warranting randomized trials on the topic. 
Personalized rescue therapies
Prone position is the most effective way to increase lung 
protection and decrease mortality: its use is strongly 
advised in ARDS patients with P/F ≤150 mmHg (27). 
Prone position recruits atelectatic lung areas, improves 
ventilation/perfusion matching and limits inhomogeneities, 
also ameliorating right ventricular function. Thus, the 
more these derangements are present the more effective 
prone position should be. Nevertheless, identifying patients 
who most benefit from prone position remains a clinical 
challenge. The improvement in oxygenation determined 
by prone position does not predict decreased mortality and 
should not be used as clinical criterion to decide to continue 
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the procedure. Indeed, prone position leads to a change 
in the shape of the wall and the thorax, thus inducing a 
redistribution of VT towards the dorsal areas, thereby 
favoring a more homogeneous distribution of ventilation (5). 
As lung protection is probably the true “life-saving” effect 
of prone positioning, we could speculate its benefit would 
be maximal in subjects whose response to prone position 
in terms of increased lung homogeneity is more evident. 
However, assessing homogeneity at the bedside requires 
sophisticated imaging techniques (18). In the clinical 
scenario, arterial CO2 response to prone position, which 
is directly related to changes in both lung recruitment and 
overdistension, could be used as surrogate to confirm lung 
protection and guide personalized application of prone 
position. Hence, previous study showed that subjects 
improving PaCO2 have a higher survival rate at 28 days 
compared to non-responders. Another method to identify 
subjects more likely to benefit from prone position is once 
again to differentiate focal vs. non-focal ARDS: indeed, 
in focal ARDS, pronation recruits the non-aerated lung 
(i.e., atelectatic zones), avoiding hyperinflation of the well-
ventilated areas and over-distention (28). 
When prone position is insufficient to determine an 
improvement in oxygenation and lung healing, extracorporeal 
membrane oxygenation (ECMO) should be considered. 
A recent prospective cohort study showed how ECMO 
could be useful in severe ARDS patients to normalize gas 
exchange despite ultra-protective mechanical ventilation and 
lung rest, potentially favoring reduction of edema and lung 
recovery (29). Moreover, in the recent EOLIA trial, ECMO 
was used as a rescue therapy in severe ARDS patients and 
survival improved almost significantly compared to standard 
protective ventilation (30); in a Bayesian analysis, ECMO 
was shown to be more effective than standard protective 
ventilation therapy in reducing mortality once physician’s 
confidence in the effectiveness of the treatment was high, 
which may derive from precise recognition of sub-phenotypes 
more likely to respond (31,32).
Less evidence is available concerning ECCO2R use 
in ARDS patients: while it could be useful to reduce VT 
to less than 6 mL/kg, the effect on oxygenation is nil or 
even negative. Indeed, ECCO2R could induce hypoxemia 
through multiple mechanisms including lung collapse and 
change in the respiratory quotient. However, at variance 
from ECMO, during ECCO2R hypoxic vasoconstriction 
remains intact and this optimizes ventilation/perfusion 
matching Probably, this could support use in focal ARDS as 
it could improve the perfusion of the well-ventilated areas, 
avoiding to “wasted” blood flow through atelectasis zones. 
A recent analysis confirmed the possibility of personalizing 
use of ECCO2R and suggested that the lung-protective 
benefits of ECCO2R increases with lower respiratory system 
compliance and higher alveolar dead space fraction but not 
with lower P/F ratio (33).
The LIVE study: the first trial on a personalized 
approach to ARDS
The recently published LIVE study was the first trial to test 
personalized mechanical ventilator settings in moderate-
to-severe ARDS (1). In the intervention group, VT, PEEP, 
use of prone position and recruitment maneuvers were 
personalized according to lung morphology (i.e., focal vs. 
non-focal), which was assessed by computer tomography 
(CT) or chest X-ray: subjects with focal ARDS (i.e., 
collapse limited to the dorsal lung regions) were treated 
with higher VT (up to 8 mL/kg), lower PEEP and prone 
position; subjects with non-focal diffuse ARDS, instead, 
were managed with lower VT, more aggressive recruitment 
and higher PEEP to reach upper limit of protective plateau 
pressure. In control group, VT was set at 6 mL/kg, low 
PEEP based on the degree of oxygenation impairment was 
delivered, and prone position use was considered a rescue 
strategy. Primary study outcome was mortality at 90 days 
and study numerosity was 420 subjects. No significant 
difference between the two groups was shown by univariate 
analysis (mortality rate was 27% vs. 27%; HR 0.96; 95% CI, 
0.66–1.4; P=0.84). Secondary outcomes were not improved, 
either. 
However, this study might have disclosed another result 
that could foster our knowledge on ARDS pathophysiology 
in unexpected directions. Indeed, experts post-hoc review 
of the on-site classification of focal and non-focal ARDS 
discovered that misclassification occurred in a high 
percentage of subjects (n=85, 21% of total population). 
When analyses were performed again considering 
misclassification, the 90-day mortality of the misclassified 
patients was higher in the personalized group [26 (65%) 
of 40 patients] than in the control group [18 (32%) of 57 
patients; HR 2.8; 95% CI, 1.5–5.1; P=0.012]. Moreover, for 
the correctly classified subjects, mortality was lower in the 
personalized group [29 (19%) of 156 patients] than in the 
control group [58 (28%) of 204 subjects; HR 0.6; 95% CI, 
0.37–0.99; P=0.042]. Although being secondary and lacking 
the adequate power, both these results could shed new light 
on the personalized treatment of ARDS sub-phenotypes. 
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Indeed, in patients with focal ARDS, the use of high levels 
of PEEP and lower volumes together with recruitment 
maneuvers could have caused over-distention, worsening 
of the respiratory system compliance, increased lung stress 
and dead space and impaired right ventricular function. 
On the other hand, in non-focal ARDS, where the damage 
is patchy and the amount of recruitable areas is higher, 
lower levels of PEEP could have caused higher shunt and 
FiO2 requirements, while higher VT could have increased 
lung strain and atelectrauma. The decrease in mortality 
of correctly classified subjects, instead, strongly support 
the need of comprehensive personalized assessment of the 
ventilation strategy when treating a moderate-severe ARDS 
patient.
In the real-life of our ICUs, experts in lung morphology 
are not always readily available and misclassification could 
be even more frequent than in a specific clinical trial. Thus, 
clinical translation of the new findings by the LIVE study 
requires thoughtful understanding of the most adequate 
method to classify subjects. Available options could be more 
solid quantitative tests of recruitability or the support by 
artificial intelligence. For quantitative tests of recruitment, 
bedside dynamic imaging tools such as electrical impedance 
tomography or ultrasound could outperform statistic chest 
X-rays and CT scans used in the LIVE study. Artificial 
intelligence, instead, could compare almost instantaneously 
the actual imaging from the patient to extremely large 
datasets of images pre-classified by experts. Moreover, 
combination of multiple indexes integrating clinical 
condition with physiology and biological markers could 
be key to fully disclose sub-phenotypes at the bedside, as 
ARDS is a continuum of pathophysiological patterns with 
blurred borders.
Personalized approach at the bedside
All the evidences discussed so far indicate that the paradigm 
of ARDS management shifted from correcting gas exchange 
to ensuring lung protection and limiting VILI (Table 1). 
Reduction of VT to 6 mL/kg PBW and, in moderate-to-
severe patients, higher PEEP and prone positioning should 
be considered mandatory if no major contraindication exists 
(e.g., hemodynamic instability).
However, contemporary ICU physicians should also 
aim to implement physiological bedside measures to assess 
specific patient characteristics and further characterize 
ARDS subphenotypes. Ideally, each ventilatory setting 
should be accurately tailored to individual physiology. VT-
reduction below 6 mL/kg PBW should be considered if 
indexes of regional (measured by electrical impedance 
tomography)  or  g loba l  (measured  by  a i rway  or 
transpulmonary elastance-derived plateau pressure) lung 
stress and strain (measured by airway or transpulmonary 
driving pressure or by dilution methods for lung aeration) 
exceed safety thresholds. On the other hand, VT higher than 
6 mL/kg PBW can be considered in hypercapnic ARDS 
patients if safety thresholds aren’t crossed. Higher PEEP 
should be selected after thorough assessment of actual lung 
recruitability for which different techniques exist, based 
on respiratory mechanics or imaging tools. Finally, rescue 
therapies should be considered for more severe patients in 
terms of worsen oxygenation and/or more impaired lung 
mechanics and/or lower residual lung aeration (i.e., smaller 
baby lung).
Conclusions
Personalized treatment of ARDS represents the most 
fascinating challenge for researchers and clinicians in 
the next few years. Each component of treatment could 
be personalized after allocating patients to consistent 
biologically- and physiologically-sound sub-phenotypes. 
Given the magnitude of the required effort, caregivers at 
all the levels should feel involved: from funding agencies 
to institutions, to doctors, nurses and families, so that the 
focus of personalized treatment could shift from simply 
improve mortality to long-term functional outcomes.
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